ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
64,321.25
1.83%
S&P 500
5,180.74
1.03%
Dow Jones
38,852.27
0.46%
US Dollar vs Yen
154.298
0.04%
Brent Oil
83.49
0.02%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. EyePoint Pharmaceuticals Inc (EYPT)

  7. EyePoint Pharmaceuticals Inc (EYPT) ニュース

EYPT

EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:EYPT
日付受信時刻ニュースソース見出しコード企業名
2024/05/0622 : 25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/05/0620 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic RetinopathyNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/04/1620 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/04/0220 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina SpecialistsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/1820 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0903 : 53Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0721 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0721 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate DevelopmentsNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0507 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0507 : 37Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0421 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/03/0421 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical OfficerNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/2921 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/2721 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/2307 : 08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1621 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1511 : 08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1407 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1407 : 39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1407 : 38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1407 : 38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1407 : 37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/1402 : 00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/0607 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/0406 : 20GlobeNewswire Inc.EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular DegenerationNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/02/0306 : 22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/01/3121 : 00GlobeNewswire Inc.EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/01/3106 : 53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/01/3007 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
2024/01/3007 : 51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EYPTEyePoint Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EYPT

最近閲覧した銘柄

NYSE
DIS
Walt Disney
AMEX
XLF
Financial Select Sector
CCOM
US100
US Tech 100
USOTC
RHHBY
Roche (QX)
NYSE
MRK
Merck
CCOM
SILVER
SILVER
USOTC
ADDYY
Adidas (QX)
NASDAQ
AMZN
Amazon.com
NASDAQ
GOOGL
Alphabet
NYSE
MCD
McDonalds
PM
XAUUSD
Gold vs US Dollar
COIN
ETHUSD
Ethereum
AMEX
XLV
Health Care Select Sector
NYSE
VZ
Verizon Communications
AMEX
XLE
Energy Select Sector SPDR
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有